Canada · Delayed Price · Currency is CAD Entheon Biomedical Statistics
Total Valuation
CSE:ENBI.X has a market cap or net worth of CAD 831,536. The enterprise value is 507,225.
| Market Cap | 831,536 |
| Enterprise Value | 507,225 |
Important Dates
The next estimated earnings date is Friday, September 18, 2026.
| Earnings Date | Sep 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CSE:ENBI.X has 13.86 million shares outstanding. The number of shares has increased by 27.09% in one year.
| Current Share Class | 13.86M |
| Shares Outstanding | 13.86M |
| Shares Change (YoY) | +27.09% |
| Shares Change (QoQ) | -32.75% |
| Owned by Insiders (%) | 2.91% |
| Owned by Institutions (%) | n/a |
| Float | 13.46M |
Valuation Ratios
The trailing PE ratio is 19.18.
| PE Ratio | 19.18 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.73 |
| P/TBV Ratio | 1.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 11.70 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.16
| Current Ratio | 12.16 |
| Quick Ratio | 11.84 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 9.47% and return on invested capital (ROIC) is -43.68%.
| Return on Equity (ROE) | 9.47% |
| Return on Assets (ROA) | -41.05% |
| Return on Invested Capital (ROIC) | -43.68% |
| Return on Capital Employed (ROCE) | -66.73% |
| Weighted Average Cost of Capital (WACC) | 12.52% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.84% in the last 52 weeks. The beta is 1.50, so CSE:ENBI.X's price volatility has been higher than the market average.
| Beta (5Y) | 1.50 |
| 52-Week Price Change | -36.84% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.14 |
| Relative Strength Index (RSI) | 41.31 |
| Average Volume (20 Days) | 39,223 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -319,967 |
| Pretax Income | 43,363 |
| Net Income | 43,363 |
| EBITDA | n/a |
| EBIT | -319,967 |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 324,308 in cash and no debt, with a net cash position of 324,308 or 0.02 per share.
| Cash & Cash Equivalents | 324,308 |
| Total Debt | n/a |
| Net Cash | 324,308 |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 479,508 |
| Book Value Per Share | 0.03 |
| Working Capital | 474,508 |
Cash Flow
| Operating Cash Flow | -85,076 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -85,076 |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CSE:ENBI.X does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.09% |
| Shareholder Yield | -27.09% |
| Earnings Yield | 5.21% |
| FCF Yield | -10.23% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 1, 2024. It was a reverse split with a ratio of 0.1.
| Last Split Date | Mar 1, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |